医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CORRECTING and REPLACING IDT Offers Preferred Pricing and Early Access to Complete Portfolio of Coronavirus Research Tools

2020年01月31日 AM04:18
このエントリーをはてなブックマークに追加


 

CORALVILLE, Iowa

Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

IDT OFFERS PREFERRED PRICING AND EARLY ACCESS TO COMPLETE PORTFOLIO OF CORONAVIRUS RESEARCH TOOLS

Complete qPCR panel of the CDC-published sequences for coronavirus detection in addition to preferred pricing on gBlocks fragments and synthetic genes ordered for vaccine development

Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced that it is accepting pre-orders from the global public health and research communities for qPCR primers and probes designed to detect the novel coronavirus, 2019-nCoV, which had an outbreak in Wuhan, Hubei Province, China.

The United States Centers for Disease Control and Prevention (CDC) released a panel of probes and primers on Monday, January 27, 2020, designed for specific detection of the virus. IDT is accepting orders for the panel immediately and will begin shipments next week. The virus detection panels will be manufactured in IDT’s global suite of cleanrooms designed to prevent synthetic template contamination, and the panels will be formulated to meet CDC’s recommended primer-to-probe ratio. To accompany the detection panels, the company has confirmed ‘ready to deliver’ positive and negative controls for 2019-nCoV, which can be used to ensure the accuracy and reliability of test results.

IDT will also provide eBlocks™ and gBlocks™ gene fragments and synthetic genes at preferred pricing, with priority shipping to researchers pursuing rapid vaccine development or exploring therapeutic interventions for 2019-nCoV. To facilitate quick turnaround of orders, the company’s entire gene synthesis support team is standing by to assist with coronavirus projects.

Trey Martin, President of IDT commented, “Fighting emergent pathogens is among the most important efforts that researchers undertake. We’re thankful for all the researchers willing to suit up for these battles, and if we can make their progress faster or easier, we’re going to be there to help them.”

The company has opened a dedicated channel for inquiries relating to 2019-nCoV detection and vaccine development products. Researchers can email coronavirus@idtdna.com to pre-order, and for preferred pricing and priority shipping. IDT’s scientific application support team will address inquiries and guide customers through the process.

Follow IDT on Twitter @idtdna for real-time updates and insights.

About IDT

Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by researchers in diagnostic tests for many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Leuven, Belgium; and Singapore.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005794/en/

CONTACT

Brian Werger

Manager of Public Relations

800-328-2661 (US & Canada)

+1 319-626-8400 (outside US)

idtpr@idtdna.com

www.idtdna.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表